 |
|
|
|
December 2008 Cover
HIV Digests in this issue:
|
|
Could a single antiretroviral dose maintain activity for months? The answer may be yes, if the results of an early study of a novel formulation of TMC278 (rilpivirine) are any indication. Initial study findings suggest that an injected nanosuspension of the experimental NNRTI was tolerable in HIV-uninfected volunteers and showed sustained plasma concentrations through 12 weeks.
A nanosuspension is a formulation which, in an aqueous formulation, has very small crystals of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor. These crystals are made small by a milling process, which reduces them to approximately twice the diameter of an HIV particle.
from TheBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
